This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 26 open trials.
In 116 locations
What is a Clinical Trial?
There are currently 26 open trials
- A study evaluating the standard care of relapsed/refractory myeloma patients
- A study evaluating CCS1477 for the treatment of relapsed/refractory myeloma patients
- Oxford pre-cancerous disorders study (OxPLoreD)
- A study evaluating S65487 for the treatment of relapsed/refractory myeloma patients
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Using diffusion weighted MRI to measure myeloma disease burden and bone loss (LOOMIS)
- Daratumumab in combination with standard myeloma treatment
- Exercise in transplant eligible myeloma patients (PERCEPT)
- Daratumumab with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients
- Venetoclax and dexamethasone in patients with relapsed or refractory multiple myeloma (CANOVA)
- Daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed AL amyloidosis
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- Effects of an exercise programme on smouldering myeloma and MGUS
- Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma patients (MUK twelve)
- Tanezumab for bone pain in myeloma
- Donor lymphocyte infusion after stem cell transplant in myeloma (ProT4).
- CC-92480 in combination with dexamethasone in relapsed and refractory multiple myeloma
- AZD4573 in relapsed or refractory myeloma
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Observational evaluation of myeloma patients (PREAMBLE)
- MUK nine b: OPTIMUM
- CAR-T cell therapy for relapsed and/or refractory myeloma (APRIL)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- Myeloma XII (ACCoRd)
- GSK525762 trial
Trial Title:
A study evaluating the standard care of relapsed/refractory myeloma patients
Treatments:
Myeloma stage:
Relapsed, Refractory
Trial phase:
Summary:
A study evaluating the safety and effectiveness of standard care in relapsed/refractory myeloma patients who have received at least three prior treatments.
Locations:
Heartlands Hospital, Birmingham;
Southmead Hospital, Bristol;
Maidstone Hospital, Maidstone;
Nottingham University Hospitals NHS Trust;
Royal Hallamshire Hospital, Sheffield
Who can enter the study?:
Relapsed/refractory myeloma patients who have had at least three prior treatments, including an immunomodulatory drug, a proteasome inhibitor and a CD38 monoclonal antibody, and are currently receiving the standard anti-myeloma treatment.
What's involved?:
Researchers will collect information from medical records of enrolled patients to learn about their myeloma and the treatment(s) used. Patients will also be asked to complete surveys, known as patient-reported outcomes.
Patients may also be required to attend outpatient clinics for regular check-ups and tests.
Each patient enrolled in the study will be followed for up to two years
Clinical Information
(for Medical Professionals):
This study is a prospective, multinational study to assess the safety and efficacy of the current standard of care for relapsed/refractory myeloma patients in routine clinical practice.
For more information, click here.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk